Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 5, 2010, Pages 827-833

  Rischin, Danny ^a,c   Narayan, Kailash ^a,c   Oza, Amit M ^b,d   Mileshkin, Linda ^a,c   Bernshaw, David ^a   Choi, Jimin ^a   Hicks, Rodney ^b,d   McClure, Bev ^a   Fyles, Anthony ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cervical cancer; Chemoradiation; Clinical trials; Hypoxia; Tirapazamine

Indexed keywords

AZOMYCINARABINOSIDE F 18; CISPLATIN; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; BLEEDING; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEARING LOSS; HEMODYNAMICS; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LOW DRUG DOSE; LUNG EMBOLISM; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VAGINA BLEEDING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; TRIAZINES; UTERINE CERVICAL NEOPLASMS;

EID: 77956799091     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181dc827e     Document Type: Article

References (20)

1. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144Y1153.
2. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340: 1137Y1143.
3. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005:CD002225.
4. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002;20:680Y687.
5. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48:149Y156.
6. Hockel M, Knoop C, Schlenger K, et al. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol. 1994;345:445Y450.
7. Knocke TH, Weitmann HD, Feldmann HJ, et al. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 1999;53: 99Y104.
8. Brown JM. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer. 1993;67: 1163Y1170.
9. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 1993;53:4633Y4636.
10. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79Y87.
11. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19: 535Y542.
12. Rischin DP, O'Sullivan L, Giralt BJ, et al. Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. In Press.
13. Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2000;48: 791Y795.
14. Lee DJ, Trotti A, Spencer S, et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A phase II study. Int J Radiat Oncol Biol Phys. 1998;42: 811Y815.
15. Von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced nonYsmall-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated nonYsmall-cell lung tumors. J Clin Oncol. 2000;18:1351Y1359.
16. Bachtiary B, Selzer E, Knocke TH, et al. Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: Impact on progression-free survival. Cancer Lett. 2002;179: 197Y203.
17. Le QT, Moon J, Redman M, et al. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009;27:3014Y3019.
18. Monk BJ, Ali S, Gaffney DK. When is being in a hurry going too fast? Lessons learned from clinical trials in cervical cancer. Gynecol Oncol. 2009;113:1Y3.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31Y41.
20. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomographyYdetected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098Y2104.